Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra, Holly Tovey, Alex Pearson, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 223

Showing 26-50 of 223 citing articles:

CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors
Zhiwen Shi, Jianfeng Shen, Junjun Qiu, et al.
Theranostics (2021) Vol. 11, Iss. 15, pp. 7175-7187
Open Access | Times Cited: 44
Tackling PARP inhibitor resistance
Kasper Fugger, Graeme Hewitt, Stephen C. West, et al.
Trends in cancer (2021) Vol. 7, Iss. 12, pp. 1102-1118
Closed Access | Times Cited: 42
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
Lola Paulet, Alexis Trécourt, Alexandra Léary, et al.
European Journal of Cancer (2022) Vol. 166, pp. 87-99
Open Access | Times Cited: 35
Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort
Benjamin D. Leibowitz, Bonnie V. Dougherty, Joshua S. K. Bell, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 35
The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
Ziyi Wang, Renxiang Jia, Linlin Wang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 35
BRCA1 deficiency specific base substitution mutagenesis is dependent on translesion synthesis and regulated by 53BP1
Dan Chen, Judit Z. Gervai, Ádám Póti, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 31
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Maria Clara Saad Menezes, Farah Raheem, Lida A. Mina, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4332-4332
Open Access | Times Cited: 30
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
Erica S. Tsang, Veronika Csizmók, Laura M. Williamson, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 18
Identification of cuproptosis-related miRNAs in triple-negative breast cancer and analysis of the miRNA–mRNA regulatory network
Yitao Wang, Jundan Wang, Jing Jiang, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28242-e28242
Open Access | Times Cited: 7
DNA damage response in breast cancer and its significant role in guiding novel precise therapies
Jiayi Li, Ziqi Jia, Dong Lin, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Guanosine diphosphate–mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer
Jia-Han Ding, Yi Xiao, Fan Yang, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 728
Closed Access | Times Cited: 6
A review on trends in development and translation of omics signatures in cancer
Wei Ma, Wenshu Tang, Jamie Sui-Lam Kwok, et al.
Computational and Structural Biotechnology Journal (2024) Vol. 23, pp. 954-971
Open Access | Times Cited: 6
Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
Pierre Loap, Delphine Loirat, Frédérique Berger, et al.
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 109, Iss. 2, pp. 436-440
Closed Access | Times Cited: 41
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
Dawn Janysek, Jennifer Kim, Pascal H. G. Duijf, et al.
Translational Oncology (2021) Vol. 14, Iss. 3, pp. 101012-101012
Open Access | Times Cited: 39
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Elisa Agostinetto, Daniel Eiger, Kevin Punie, et al.
Current Oncology Reports (2021) Vol. 23, Iss. 5
Closed Access | Times Cited: 38
Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation
Marjolijn M. Ladan, Dik C. van Gent, Agnes Jager
Cancers (2021) Vol. 13, Iss. 5, pp. 1004-1004
Open Access | Times Cited: 37
CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis
Anni Laine, Srikar G. Nagelli, Caroline Farrington, et al.
Cancer Research (2021) Vol. 81, Iss. 16, pp. 4319-4331
Open Access | Times Cited: 37
Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes
Naser Ansari‐Pour, Yonglan Zheng, Toshio F. Yoshimatsu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 35
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
Even H Rustad, Ferran Nadeu, Nicos Angelopoulos, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 34
Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction
Ying‐Cheng Chiang, Po‐Han Lin, Wen‐Fang Cheng
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 33
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers
Lingling Zhu, Jiewei Liu, Jiang Chen, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 33
PARP mediated DNA damage response, genomic stability and immune responses
Chunyan Zong, Tianyu Zhu, Jie He, et al.
International Journal of Cancer (2021) Vol. 150, Iss. 11, pp. 1745-1759
Open Access | Times Cited: 33
Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies
Smarakan Sneha, Simon C. Baker, Andrew R. Green, et al.
Biomedicines (2021) Vol. 9, Iss. 3, pp. 290-290
Open Access | Times Cited: 32
Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non–Squamous Non–Small Cell Lung Cancer
Ramaswamy Govindan, Michael J. Lind, Amelia Insa, et al.
Clinical Lung Cancer (2022) Vol. 23, Iss. 3, pp. 214-225
Open Access | Times Cited: 25
Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy
Jifa Zhang, Chengcan Yang, Pan Tang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6803-6825
Closed Access | Times Cited: 25

Scroll to top